We are live on ! Find out more
SOCM

SR One Capital Management Portfolio holdings

AUM $915M
1-Year Est. Return 209.71%
This Fund
S&P 500
This Quarter Est. Return
+15.58%
1 Year Est. Return
+209.71%
3 Year Est. Return
+484.66%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$706M
AUM Growth
+$15M
Cap. Flow
-$7M
Cap. Flow %
-0.99%
Top 10 Hldgs %
97.72%
Holding
13
New
1
Increased
2
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
OCS icon
Oculis Holding
OCS
+$6.37M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$4.53M
3
ZBIO
Zenas BioPharma
ZBIO
+$4.15M

Top Sells

Rank Stock Value
1
MLYS icon
Mineralys Therapeutics
MLYS
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBIO
1
Zenas BioPharma
ZBIO
$2.04B
$183M 25.9%
5,037,854
+126,315
+3% +$4.15M
ACLX
2
DELISTED
Arcellx
ACLX
$153M 21.66%
2,346,630
– –
CRSP icon
3
CRISPR Therapeutics
CRSP
$4.77B
$107M 15.14%
2,038,763
– –
DSGN icon
4
Design Therapeutics
DSGN
$788M
$61.2M 8.67%
6,526,476
– –
MLYS icon
5
Mineralys Therapeutics
MLYS
$2.31B
$56.8M 8.03%
1,563,966
-549,967
-26% -$22.1M
SPRY icon
6
ARS Pharmaceuticals
SPRY
$559M
$46.8M 6.62%
4,012,903
– –
ORIC icon
7
Oric Pharmaceuticals
ORIC
$1.2B
$37.8M 5.34%
4,514,929
– –
ALMS
8
Alumis Inc
ALMS
$3.69B
$19.1M 2.71%
1,959,896
– –
ORKA
9
Oruka Therapeutics
ORKA
$5.9B
$13M 1.85%
430,330
– –
OCS icon
10
Oculis Holding
OCS
$677M
$12.8M 1.81%
641,022
+318,522
+99% +$6.37M
ENGN icon
11
enGene Therapeutics
ENGN
$118M
$6.75M 0.96%
747,750
– –
NKTX icon
12
Nkarta
NKTX
$154M
$6.17M 0.87%
3,333,333
– –
RARE icon
13
Ultragenyx Pharmaceutical
RARE
$2.56B
$3.17M 0.45%
+137,753
New +$4.53M

Similar funds

PTC
Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return
DWP
Destiny Wealth Partners Tavares, Florida $914M AUM 18.14% 1-Year Est. Return
BDF
Black Diamond Financial Towson, Maryland $916M AUM 15.95% 1-Year Est. Return
SC
Sierra Capital Miami, Florida $918M AUM 8.25% 1-Year Est. Return
SI
Symmetry Investments St Helier, Jersey $913M AUM 30.59% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $913M AUM 11.84% 1-Year Est. Return
SAA
Southeast Asset Advisors Thomasville, Georgia $913M AUM 25.32% 1-Year Est. Return
GC
Greenvale Capital London, United Kingdom $912M AUM 34.2% 1-Year Est. Return

SR One Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, SR One Capital Management held 13 positions worth $706M, up 2.2% from $691M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

SR One Capital Management's Q4 2025 filing shows 1 new, 2 increased and 1 reduced positions. Its largest new stake was Ultragenyx Pharmaceutical: 137,753 shares worth $3.17M. The largest sale was Mineralys Therapeutics, an estimated $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • SR One Capital Management's largest Q4 2025 buy was Ultragenyx Pharmaceutical: 137,753 shares worth $3.17M.
  • SR One Capital Management added most to Oculis Holding in Q4 2025, an estimated $6.37M increase.
  • SR One Capital Management's biggest Q4 2025 reduction was Mineralys Therapeutics, cutting an estimated $22.1M.
  • SR One Capital Management's ten largest holdings make up 98% of its $706M portfolio in Q4 2025.
  • SR One Capital Management opened 1 new position and closed 0 in Q4 2025.
  • SR One Capital Management's portfolio value rose 2.2% quarter-over-quarter to $706M.

Based on SR One Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.